Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

Kids with alopecia areata had lower vitamin D levels than healthy kids.

Children with autoimmune hair loss have similar vitamin D levels to healthy kids, suggesting no extra screening is needed.

Vitamin D3 helps treat mild to moderate alopecia areata, especially when combined with other treatments.

Intralesional methotrexate and triamcinolone acetonide are more effective than Vitamin D3 for treating alopecia areata.

Combining DPCP with PRP doesn't improve hair regrowth in alopecia areata.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

People with alopecia areata often have low vitamin D levels, which may worsen their hair loss.

Low vitamin D levels might indicate more severe hair loss in alopecia areata patients.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Tofacitinib may help treat severe hair loss, but more research is needed.

Baricitinib is effective and safe for treating severe alopecia areata.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Alefacept does not effectively treat severe alopecia areata.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

This therapy effectively treats resistant alopecia areata with minimal side effects.

COVID-19 doesn't make alopecia areata worse.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.